KR20220119367A - 파네소이드 x 수용체(fxr)-매개 전사 반응의 유도 또는 증대 방법 - Google Patents

파네소이드 x 수용체(fxr)-매개 전사 반응의 유도 또는 증대 방법 Download PDF

Info

Publication number
KR20220119367A
KR20220119367A KR1020227017124A KR20227017124A KR20220119367A KR 20220119367 A KR20220119367 A KR 20220119367A KR 1020227017124 A KR1020227017124 A KR 1020227017124A KR 20227017124 A KR20227017124 A KR 20227017124A KR 20220119367 A KR20220119367 A KR 20220119367A
Authority
KR
South Korea
Prior art keywords
compound
fxr
subject
disease
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227017124A
Other languages
English (en)
Korean (ko)
Inventor
영치 쳉
윙 람
Original Assignee
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예일 유니버시티 filed Critical 예일 유니버시티
Publication of KR20220119367A publication Critical patent/KR20220119367A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020227017124A 2019-11-20 2020-11-19 파네소이드 x 수용체(fxr)-매개 전사 반응의 유도 또는 증대 방법 Pending KR20220119367A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937964P 2019-11-20 2019-11-20
US62/937,964 2019-11-20
PCT/US2020/061257 WO2021102124A1 (en) 2019-11-20 2020-11-19 Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response

Publications (1)

Publication Number Publication Date
KR20220119367A true KR20220119367A (ko) 2022-08-29

Family

ID=75981072

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017124A Pending KR20220119367A (ko) 2019-11-20 2020-11-19 파네소이드 x 수용체(fxr)-매개 전사 반응의 유도 또는 증대 방법

Country Status (7)

Country Link
US (1) US20220409631A1 (https=)
EP (1) EP4061377A4 (https=)
JP (1) JP2023502251A (https=)
KR (1) KR20220119367A (https=)
CN (1) CN114786678A (https=)
TW (1) TW202128200A (https=)
WO (1) WO2021102124A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI819307B (zh) * 2020-05-19 2023-10-21 吉亞生物科技股份有限公司 萜類化合物在治療或預防纖維化疾病中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9713605B2 (en) * 2011-11-18 2017-07-25 Simpson Biotech Co., Ltd. Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death
CN103159732A (zh) * 2011-12-15 2013-06-19 台湾利得生物科技股份有限公司 一种聚乙炔化合物、含其中的萃取物及其应用
JP2014139153A (ja) * 2012-08-24 2014-07-31 Taiwan Antitumer Biotech Co Ltd 腫瘍の治療及び／又は予防における抗がん薬と組み合わせたアントシン誘導体
WO2015065983A1 (en) * 2013-10-29 2015-05-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
CN104606260B (zh) * 2014-12-25 2018-01-30 恩扬生物科技股份有限公司 牛樟芝子实体萃取物用于改善化疗副作用的用途
TWI623749B (zh) * 2015-04-30 2018-05-11 吳永昌 一種樟芝萃取物製備及分析方法
CN105311036B (zh) * 2015-11-26 2017-11-21 中国农业大学 樟芝酸h在防治药物性肝损伤中的应用

Also Published As

Publication number Publication date
EP4061377A4 (en) 2023-11-29
CN114786678A (zh) 2022-07-22
JP2023502251A (ja) 2023-01-23
EP4061377A1 (en) 2022-09-28
US20220409631A1 (en) 2022-12-29
TW202128200A (zh) 2021-08-01
WO2021102124A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
Chenxu et al. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress
KR102459500B1 (ko) 퀘르세틴 배당체를 함유하는 근위축 억제제
Park et al. Dehydrocostuslactone inhibits LPS-induced inflammation by p38MAPK-dependent induction of hemeoxygenase-1 in vitro and improves survival of mice in CLP-induced sepsis in vivo
EP2359828A1 (en) HDAC inhibitors and hormone targeted drugs for the treatment of cancer
JP6456383B2 (ja) イソチオシアネート系化合物と抗癌薬の併用
RU2644635C2 (ru) Системы, способы и составы для лечения рака
CN102481253B (zh) 包含羟基氯喹的用于抗癌治疗的局部投药用注射剂组合物
JP2010502730A (ja) 癌の治療法
US20090264483A1 (en) METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
KR102358632B1 (ko) 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
US20160129012A1 (en) Compositions and methods for treating allergic inflammation through inhibition of ntrk1
Kounatidis et al. The many facets of PPAR-γ agonism in obesity and associated comorbidities: benefits, risks, challenges, and future directions
US10307401B2 (en) Compositions and methods for treatment of prostate cancer
US20230014055A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
Tang et al. Tetrahydroberberrubine exhibits preventive effect on obesity by activating PGC1α-mediated thermogenesis in white and brown adipose tissue
KR20220119367A (ko) 파네소이드 x 수용체(fxr)-매개 전사 반응의 유도 또는 증대 방법
WO2015157500A1 (en) Class iia hdac inhibitors for the treatment of infection
US20170049746A1 (en) Uses of butylidenephthalide
Wen et al. Bromelain improves decrease in defecation in postoperative rats: Modulation of colonic gene expression of inducible nitric oxide synthase
EP2895149B1 (en) Synergistic anti-cancer composition and a process for the preparation thereof
HK40077325A (en) Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response
EP3338775B1 (en) Use of butylidenephthalide
Van Neerven et al. Systemic but not local administration of retinoic acid reduces early transcript levels of pro-inflammatory cytokines after experimental spinal cord injury
CN115177608A (zh) 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用
US12447147B2 (en) Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902